Accelerate Diagnostics logo
Accelerate Diagnostics AXDX
report update icon

Quarterly report 2024-Q3
added 05-23-2026

Accelerate Diagnostics Cash Flow 2024-2010 | AXDX

Brief cash flow overview of Accelerate Diagnostics

The comparison covers five available annual reports between 2020 and 2024.

The latest year produced an operating outflow of -$24.2 million. A return to positive cash generation is important.

Core operations generated cash in 0 of five years. Frequent negative periods raise financial risk.

A $9.4 million reduction in working capital needs released cash equal to 80.6% of revenue.

What the cash flows show

Accelerate Diagnostics has limited cash flow resilience; a return to stable positive cash generation is the main condition for improvement.

Annual Cash Flow Accelerate Diagnostics

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Operating Cash Flow

-24.2 M -40.2 M -48.7 M -47.3 M -50.4 M -64.8 M -67.8 M -55.7 M -53.4 M -35.1 M -18.8 M -9.75 M -816 K 448 K -

Depreciation & Amortization

1.4 M 1.3 M 1.7 M 2 M 2.4 M 2.3 M 2.5 M 2.2 M 2.3 M 1.8 M 817 K 286 K 2 K 2.4 K -

Accounts Payables

4.84 M 4.8 M 4.5 M 1.98 M 1.29 M 2.35 M 1.32 M 2.08 M 992 K 2.62 M 2.13 M 540 K 300 K 35 K -

Accounts Receivables

2.04 M 2.62 M 2.4 M 2.32 M 1.55 M 3.22 M 1.86 M 1.95 M 34 K 77 K 78 K 24.4 K 764 K 596 K -

Total Inventories

2.85 M 3.31 M 5.19 M 5.07 M 9.22 M 8.06 M 7.75 M 8.06 M - - - - 10.3 K 30.3 K -

All numbers in USD currency

Quarterly Cash Flow Accelerate Diagnostics

2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

-19.1 M -16 M -8.45 M - -32.4 M -24.2 M -13.4 M - -39.2 M -25.6 M -12.6 M - -35.4 M -22.9 M -13.4 M - -40.1 M -27.4 M -17.6 M - -50.9 M -33.6 M -19.5 M - -53.4 M -35.4 M -16.1 M - -42.5 M -28.1 M -15.5 M - -40.6 M -28.1 M -13.2 M - -25.2 M -16.4 M -6.96 M - -14 M -7.8 M -3.67 M - -7 M -4.18 M -2.27 M - -432 K -157 K -99.7 K - -99.7 K 238 K -99.7 K

Depreciation & Amortization

343 K 351 K 331 K - 315 K 354 K 355 K - 381 K 443 K 500 K - 487 K 493 K 600 K - 600 K 600 K 600 K - 600 K 500 K 600 K - 662 K 533 K 539 K - 550 K 540 K 505 K - 598 K 605 K 542 K - 465 K 403 K 326 K - 251 K 150 K 134 K - 84.2 K 70.6 K 36.4 K 515 516 515 515 599 515 1.2 K 515

Accounts Payables

4.71 M 3.76 M 5.11 M 4.8 M 4.81 M 4.03 M 3.52 M 4.5 M 2.82 M 2.22 M 2.72 M 1.98 M 2.33 M 1.88 M 1.92 M 1.29 M 2.37 M 2.7 M 3.4 M 2.35 M 2.28 M 1.82 M 2.5 M 1.32 M 1.56 M 2.36 M 2.76 M 2.08 M 1.37 M 1.53 M 1.26 M 992 K 2.4 M 1.79 M 2.67 M 2.62 M 1.55 M 1.74 M 2.36 M 2.13 M 1.1 M 1.3 M 718 K 540 K 6.76 K 322 K 29 K 300 K 50 K 101 K 56.7 K 74.8 K 56.7 K 35 K 35 K

Accounts Receivables

2.03 M 2.29 M 2.22 M 2.62 M 2.67 M 2.34 M 2.43 M 2.42 M 2.39 M 2.94 M 2.11 M 2.32 M 2.27 M 2.11 M 1.98 M 1.55 M 2.61 M 2.59 M 3.14 M 3.22 M 2.64 M 1.91 M 1.95 M 1.86 M 1.44 M 1.82 M 1.06 M 1.95 M 1.11 M 682 K 551 K 34 K 159 K 169 K 77 K 77 K 742 K 143 K 92 K 78 K 89 K 40 K 40 K 24 K 106 K 818 K 794 K 764 K 600 K 596 K 761 K 1.34 M 761 K 596 K 596 K

Total Inventories

2.98 M 3.22 M 3.25 M 3.31 M 3.55 M 5.11 M 5.27 M 5.19 M 5.39 M 5.3 M 5.5 M 5.07 M 9.73 M 9.57 M 9.78 M 9.22 M 9.46 M 8.72 M 8.53 M 8.06 M 7.88 M 8.3 M 8.6 M 7.75 M 9.41 M 11.3 M 10.1 M 8.06 M 7.34 M 5.72 M 4.36 M - - - - - - - - 620 K - - - - - - 10.3 K - 30.3 K 30.3 K 30.3 K 30.3 K 30.3 K 30.3 K 30.3 K

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Accelerate Diagnostics, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Diagnostics research sector

Issuer Price % 24h Market Cap Country
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Biomerica Biomerica
BMRA
$ 2.14 1.9 % $ 4.92 M usaUSA
BioNano Genomics BioNano Genomics
BNGO
$ 1.17 0.88 % $ 6.37 M usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Co-Diagnostics Co-Diagnostics
CODX
$ 1.21 0.79 % $ 1.61 M usaUSA
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Brainsway Ltd. Brainsway Ltd.
BWAY
$ 14.3 0.7 % $ 486 M israelIsrael
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 242.76 0.02 % $ 26.9 B usaUSA
Celcuity Celcuity
CELC
$ 88.44 3.05 % $ 4.14 B usaUSA
Charles River Laboratories International Charles River Laboratories International
CRL
$ 291.5 0.16 % $ 14.4 B usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 6.77 1.18 % $ 27 M israelIsrael
DexCom DexCom
DXCM
$ 90.82 1.71 % $ 35.4 B usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Soleno Therapeutics Soleno Therapeutics
SLNO
- - $ 2.69 B usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
$ 1 398.58 0.64 % $ 28.8 B schweizSchweiz
Psychemedics Corporation Psychemedics Corporation
PMD
- -1.84 % $ 15.3 M usaUSA
Myriad Genetics Myriad Genetics
MYGN
$ 3.16 1.92 % $ 293 M usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
ENDRA Life Sciences ENDRA Life Sciences
NDRA
$ 5.01 4.53 % $ 3.94 M usaUSA
NeoGenomics NeoGenomics
NEO
$ 18.05 7.31 % $ 2.31 B usaUSA
Syneos Health Syneos Health
SYNH
- - $ 4.46 B usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA
Organovo Holdings Organovo Holdings
ONVO
- -2.3 % $ 19.4 M usaUSA
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
National Research Corporation National Research Corporation
NRC
$ 21.85 0.27 % $ 489 M usaUSA
T2 Biosystems T2 Biosystems
TTOO
- -39.35 % $ 313 K usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
$ 3.48 1.11 % $ 113 K usaUSA
PerkinElmer PerkinElmer
PKI
- -0.91 % $ 14.7 B usaUSA
Meridian Bioscience Meridian Bioscience
VIVO
- - $ 1.49 B usaUSA
Pacific Biosciences of California Pacific Biosciences of California
PACB
$ 1.4 0.32 % $ 420 M usaUSA
Quotient Limited Quotient Limited
QTNT
- -11.32 % $ 1.1 M schweizSchweiz
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 170.02 0.18 % $ 13.3 B irlandaIrlanda
Renalytix AI plc Renalytix AI plc
RNLX
- 5.66 % $ 22.7 M britainBritain
Interpace Biosciences Interpace Biosciences
IDXG
$ 1.45 2.11 % $ 6.41 M usaUSA
IQVIA Holdings IQVIA Holdings
IQV
$ 261.75 0.05 % $ 45 B usaUSA
Surmodics Surmodics
SRDX
- - $ 608 M usaUSA